Aside from allowing identification of individuals with increased risk of recurrence after surgery for grade I meningiomas, our data also present potential promising targets (e.g., VEGF, PlGF, and IGFBP-3) for adjuvant antiangiogenic therapy in these patients. Here, IGFBP3 is linked to meningioma.